Dynamics of anti-SARS-CoV-2 antibodies in the Albanian population: Impact of infection- and vaccine-induced immunity during the COVID-19 pandemic.

Albanian population Anti–SARS-CoV-2 antibodies COVID-19 SARS-CoV-2 seroprevalence Vaccination status

Journal

IJID regions
ISSN: 2772-7076
Titre abrégé: IJID Reg
Pays: England
ID NLM: 9918418183106676

Informations de publication

Date de publication:
Dec 2024
Historique:
received: 30 07 2024
revised: 29 08 2024
accepted: 30 08 2024
medline: 10 10 2024
pubmed: 10 10 2024
entrez: 10 10 2024
Statut: epublish

Résumé

Understanding immune response dynamics during the COVID-19 pandemic is crucial for optimizing future vaccine strategies. This study investigated the infection- and vaccine-induced SARS-CoV-2 antibody responses in the Albanian population from August 2021 to August 2022. This used a cross-sectional approach, analyzing two independent, randomly selected population samples over 1 year. Participants' demographic, health, vaccination, and COVID-19 data were collected, with blood samples assessed via enzyme linked immunosorbent assay for immunoglobulin G class anti-spike and anti-nucleocapsid antibodies. By August 2022, all individuals receiving one vaccine dose achieved antibody levels comparable to those receiving two doses (median 7.71 index ratio [IR] vs 7.00 IR). In August 2021, those with previous COVID-19 infection receiving one vaccine dose showed median anti-spike immunoglobulin G levels of 7.22 IR compared with 4.84 IR in those without previous infection receiving two doses. However, individuals aged ≥61 years required two vaccine doses to achieve similar immune responses as younger individuals with one dose. These findings underscore the importance of hybrid immunity, suggesting one vaccine dose may suffice for individuals with previous COVID-19 infection, whereas older adults require additional doses for optimal protection. This study provides insights into humoral immune response dynamics, which is crucial for refining COVID-19 vaccination strategies in middle-income countries with low vaccination coverage and high infection rates.

Identifiants

pubmed: 39386114
doi: 10.1016/j.ijregi.2024.100440
pii: S2772-7076(24)00111-5
pmc: PMC11462266
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100440

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors have no competing interests to declare.

Auteurs

Genc Sulcebe (G)

Research Center of Biotechnology and Genetics, Academy of Sciences of Albania, Tirana, Albania.
University of Medicine of Tirana, Tirana, Albania.

Alban Ylli (A)

University of Medicine of Tirana, Tirana, Albania.
Institute of Public Health, Tirana, Albania.

Fabian Cenko (F)

Catholic University "Our Lady of Good Counsel" Tirana, Tirana, Albania.

Margarita Kurti-Prifti (M)

Research Center of Biotechnology and Genetics, Academy of Sciences of Albania, Tirana, Albania.

Erkena Shyti (E)

Research Center of Biotechnology and Genetics, Academy of Sciences of Albania, Tirana, Albania.

Jonida Dashi-Pasholli (J)

Research Center of Biotechnology and Genetics, Academy of Sciences of Albania, Tirana, Albania.

Erina Lazri (E)

University of Medicine of Tirana, Tirana, Albania.

Irena Seferi-Qendro (I)

University of Medicine of Tirana, Tirana, Albania.

Melissa J Perry (MJ)

College of Public Health, George Mason University, Fairfax, USA.

Classifications MeSH